Review Article
Adenoid Cystic Carcinoma of Salivary Glands: A Ten-Year Review and an Assessment of the Current Management, Surgery, Radiotherapy, and Chemotherapy
Table 3
Update of the novel and potential therapies used in treating ACC in areas different from salivary glands.
| Study/author | Investigated target | Potential use | Comments |
| (Doddapaneni et al.) [116] | Fibroblast growth factor receptor 1 (FGFR1) | Therapeutic target | Used for ACC of lacrimal glands | (Udagawa et al.) [117] | Liposomal formulation of eribulin (E7389-LF) | Therapeutic agent | Used for ACC of salivary glands, thymus gland, and other sites | (Andersson et al.) [118] | Targeting the oncogenic transcriptional regulator MYB by inhibition of IGF1R/AKT signaling | Therapeutic target | Used for ACC of salivary glands, ACC lacrimal glands, and other sites | (Tchekmedyian et al.) [109] | The multitargeted tyrosine kinase inhibitor lenvatinib | Therapeutic agent | Used for ACC of salivary glands, lacrimal glands, breast, bronchi, and the external auditory canal |
|
|